Why the study?
CERS6 is associated with metastasis and poor prognosis in non-small cell lung cancer through C16 ceramide-mediated cell migration, but the detailed mechanism has not been elucidated.
Identifies a novel ternary complex involving LASP1, CERS6, and actin that promotes cancer cell migration in non-small cell lung cancer.
Answers are grounded in this paper and cite their sources.
LASP1-CERS6 interaction may drive NSCLC metastasis; leaves open therapeutic targeting pending functional validation.
CERS6 is associated with metastasis and poor prognosis in non-small cell lung cancer (NSCLC) patients through d18:1/C16:0 ceramide (C16 ceramide)-mediated cell migration, though the detailed mechanism has not been elucidated. In the present study, examinations including co-immunoprecipitation, liquid chromatography, and tandem mass spectrometry analysis were performed to identify a novel binding partner of CERS6. Among the examined candidates, LASP1 was a top-ranked binding partner, with the LIM domain possibly required for direct interaction. In accord with those findings, CERS6 and LASP1 were found to co-localize on lamellipodia in several lung cancer cell lines. Furthermore, silencing of CERS6 and/or LASP1 significantly suppressed cell migration and lamellipodia formation, whereas ectopic addition of C16 ceramide partially rescued those phenotypes. Both LASP1 and CERS6 showed co-immunoprecipitation with actin, with those interactions markedly reduced when the LASP1-CERS6 complex was abolished. Based on these findings, it is proposed that LASP1-CERS6 interaction promotes cancer cell migration.
No takes yet. Share an insight, caveat, or question.
Niimi et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: